A strong trend favoring the Imfinzi-based regimen was also observed for the secondary endpoint ... recommending the approval of Enhertu for certain breast cancer patients in the European Union.

The winter flu season is still in full force, according to the US Centers for Disease Control and Prevention, causing many sufferers to halt their exercise regimen. But not every illness requires ...

The winter flu season is still in full force, according to the U.S. Centers for Disease Control and Prevention, causing many sufferers to halt their exercise regimen. But not every illness ...

The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...

A strong trend favoring the Imfinzi-based regimen was also observed for the ... recommending the approval of Enhertu for certain breast cancer patients in the European Union.

BLOOM (TAMPA) – Starting a new fitness regimen can be exciting, but knowing how to approach it safely and effectively is crucial for long-term success. Jaclyn Cordeiro, founder of JACFIT 5AM ...

Positive results from the phase 3 DESTINY-Gastric04 trial (NCT04704934) have confirmed the efficacy of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with ... after a ...

Credit: SewCreamStudio / Shutterstock. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful ‘improvement’ in the DESTINY-Gastric04 Phase III trial, ...

A durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for the treatment of adults with resectable non-small cell lung cancer. The recommendation is based on ...

the FDA approved Enhertu in stomach cancer following prior treatment with a trastuzumab (Herceptin)-based regimen. That second-line nod was based on results from the phase 2 Destiny-Gastric01 ...

In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery. The Committee for Medicinal Products for ...